Modelling of patient EMS exposure: Translating pharmacokinetics of EMS in vitro and in animals into patients

Toxicology Letters

Volumn 190, Issue 3, 2009, Pages 310-316

  Lavé, Thierry ^a   Paehler, Axel ^a   Grimm, Hans Peter ^a   Gocke, Elmar ^a   Müller, Lutz ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

AUC; Cmax; Ethyl methanesulfonate; Haemoglobin ethyl valine adduct; Human modelling; Pharmacokinetics; Viracept

Indexed keywords

MESYLIC ACID ETHYL ESTER; NELFINAVIR;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CLEARANCE; CONTROLLED STUDY; DRUG CONTAMINATION; GENOTOXICITY; HUMAN; IN VITRO STUDY; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; SPECIES DIFFERENCE; TOXICOKINETICS;

ALKYLATING AGENTS; ANIMALS; AREA UNDER CURVE; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CONTAMINATION; ETHYL METHANESULFONATE; HEMOGLOBINS; HIV PROTEASE INHIBITORS; HUMANS; MACACA FASCICULARIS; MICE; MICROSOMES, LIVER; MODELS, BIOLOGICAL; MUTAGENS; NELFINAVIR; RATS; RISK ASSESSMENT; SPECIES SPECIFICITY; VALINE;

ANIMALIA; MUS; RATTUS;

EID: 69549147701     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxlet.2009.07.031     Document Type: Article

References (15)

1. Agoram B., Woltosz W.S., and Bolger M.B. Predicting the impact of physiological and biochemical processes on oral drug bioavailability. Adv. Drug Deliv. Rev. 50 Suppl. 1 (2001) S41-S67
2. Anderson B.J., and Holford N.H.G. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu. Rev. Pharmacol. Toxicol. 48 (2008) 303-332
3. Cumming R.B., and Walton M.F. Fate and metabolism of some mutagenic alkylating agents in the mouse. I. Ethyl methanesulfonate and methyl methanesulfonate at sublethal dose in hybrid males. Mutat. Res. 10 (1970) 365-377
4. Gocke, E., Müller, L., Ballantyne, M., Whitwell, J., 2009-a. Genotoxicity studies with ethyl methanesulfonate for micronuclei and lacZ gene mutation in mice. Tox. Lett.
5. Gocke E., Müller L., Pfister T., and Buergin H. Literature review on the genotoxicity, reproductive toxicity, and carcinogenicity of ethyl methanesulfonate. Tox. Lett. 190 (2009) 254-265
6. Gocke E., and Wall M. Statistical assessments for threshold dose response in mice for the induction of micronuclei and lacZ gene mutation by ethyl methanesulfonate. Tox. Lett. 190 (2009) 298-302
7. Jones H.M., Parrott N., Jorga K., and Lavé T. A novel strategy for physiologically based predictions of human pharmacokinetics. Clin. Pharmacokinet. 45 (2006) 511-542
8. Lavé T., Birnboeck H., Götschi A., Ramp T., and Paehler A. In vivo and in vitro characterization of ethyl methanesulfonate pharmacokinetics in animals and in human. Tox. Lett. 190 (2009) 303-309
9. Müller L., Gocke E., Lavé T., and Pfister T. Ethyl methanesulfonate toxicity in Viracept-a comprehensive human risk assessment based on threshold data for genotoxicity. Tox. Lett. 190 (2009) 317-329
10. Murthy M.S.S., Calleman C.J., Osterman-Golkar S., Segerbäck D., and Svensson K. Relationships between ethylation of hemoglobin, ethylation of DNA and administered amount of ethyl methanesulfonate in the mouse. Mutat. Res. 127 (1984) 1-8
11. Neumann H.G. Analysis of haemoglobin as a dose monitor for alkylating and arylating agents. Arch. Toxicol. 56 (1984) 1-6
12. Osterman-Golkar S., Ehrenberg L., Segerbäck D., and Hällström I. Evaluation of genetic risks of alkylating agents. II. Haemoglobin as a dose monitor. Mutat. Res. 34 (1976) 1-10
13. Pfister T., and Eichinger-Chapelon A. General toxicity studies with ethyl methanesulfonate. Tox. Lett. 190 (2009) 271-285
14. Recio L., Osterman-Golkar S., Csanády G.A., Turner M.J., Myhr B., Moss O., and Bond J.A. Determination of mutagenicity in tissues of transgenic mice following exposure to 1,3-butadiene and N-ethyl-N-nitrosourea. Toxicol. Appl. Pharmacol. 117 (1992) 58-64
15. Törnqvist M., Fred C., Haglund J., Helleberg H., Paulsson B., and Rydberg P. Protein adducts: quantitative and qualitative aspects of their formation, analysis and applications. J. Chromatogr. B 778 (2002) 279-308